Biotech Acquisition Company News - BIOT

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION...

Amended Statement of Ownership (sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ...

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER...

Current Report Filing (8-k)

0001825413 false 00-0000000 0001825413 2023-02-01 2023-02-01 0001825413...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE...

Statement of Ownership (sc 13g)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Current Report Filing (8-k)

0001825413 false 00-0000000 0001825413 2023-01-09 2023-01-09 0001825413...

Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account...

Proxy Statement (definitive) (def 14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 ________________ SCHEDULE 14A________________ Proxy...

Quarterly Report (10-q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ...

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFIC...

Current Report Filing (8-k)

0001825413 false 00-0000000 0001825413 2022-10-04 2022-10-04 0001825413...

Quarterly Report (10-q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ...

Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference

Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and...

Withdrawal of Registration Statement (rw)

Biotech Acquisition Company 545 West 25th Street, 20th Floor New York, New York 10001 June 17...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Biotech Acquisition Company (BIOT)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

BIOT News

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

Amended Statement of Ownership (sc 13g/a)

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)

Current Report Filing (8-k)

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Current Report Filing (8-k)

Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

Proxy Statement (definitive) (def 14a)

Quarterly Report (10-q)

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Current Report Filing (8-k)

Quarterly Report (10-q)

Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference

Withdrawal of Registration Statement (rw)

BIOT Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Biotech Acquisition Company (BIOT) News

Biotech Acquisition Company (BIOT)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

BIOT News

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

Amended Statement of Ownership (sc 13g/a)

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)

Current Report Filing (8-k)

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Current Report Filing (8-k)

Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

Proxy Statement (definitive) (def 14a)

Quarterly Report (10-q)

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Current Report Filing (8-k)

Quarterly Report (10-q)

Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference

Withdrawal of Registration Statement (rw)

BIOT Discussion

Your Recent History